Insmed (INSM) Asset Writedowns and Impairment (2011)
Insmed (INSM) posted Asset Writedowns and Impairment of $26.0 million for Q3 2011.
Powered by 
Analysis
Insmed (INSM) Asset Writedowns and Impairment (2011) Analysis & Trends
Insmed has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $26.0 million in Q3 2011.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $26.0 million in Q3 2011; TTM through Dec 2012 was $26.0 million, a 0.0% change from a year earlier, with the FY2011 full-year figure at $26.0 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $26.0 million for Q3 2011 at Insmed.
- The five-year high for Asset Writedowns and Impairment was $26.0 million in Q3 2011, with the low at $26.0 million in Q3 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |